Nebula Research & Development LLC Boosts Holdings in Keros Therapeutics, Inc. (NASDAQ:KROS)

Nebula Research & Development LLC boosted its stake in shares of Keros Therapeutics, Inc. (NASDAQ:KROS - Free Report) by 433.6% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 71,710 shares of the company's stock after acquiring an additional 58,271 shares during the quarter. Nebula Research & Development LLC owned about 0.18% of Keros Therapeutics worth $1,135,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also added to or reduced their stakes in the company. Barclays PLC increased its position in shares of Keros Therapeutics by 140.1% during the 3rd quarter. Barclays PLC now owns 60,014 shares of the company's stock valued at $3,484,000 after purchasing an additional 35,022 shares during the last quarter. SG Americas Securities LLC bought a new position in Keros Therapeutics during the fourth quarter valued at $388,000. Exchange Traded Concepts LLC purchased a new stake in shares of Keros Therapeutics in the fourth quarter valued at $99,000. China Universal Asset Management Co. Ltd. lifted its holdings in shares of Keros Therapeutics by 19.0% in the 4th quarter. China Universal Asset Management Co. Ltd. now owns 8,589 shares of the company's stock worth $136,000 after acquiring an additional 1,372 shares during the last quarter. Finally, Handelsbanken Fonder AB boosted its stake in shares of Keros Therapeutics by 11.3% during the 4th quarter. Handelsbanken Fonder AB now owns 10,800 shares of the company's stock worth $171,000 after purchasing an additional 1,100 shares during the period. 71.56% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

A number of research firms recently issued reports on KROS. Wells Fargo & Company dropped their price objective on Keros Therapeutics from $28.00 to $26.00 and set an "overweight" rating for the company in a report on Thursday, February 27th. Cantor Fitzgerald lowered shares of Keros Therapeutics from an "overweight" rating to a "neutral" rating in a research note on Tuesday, January 21st. Scotiabank reduced their price target on shares of Keros Therapeutics from $44.00 to $41.00 and set a "sector outperform" rating on the stock in a research note on Thursday, January 16th. Truist Financial lowered their price objective on shares of Keros Therapeutics from $43.00 to $25.00 and set a "buy" rating for the company in a research report on Wednesday, April 9th. Finally, Oppenheimer reduced their target price on shares of Keros Therapeutics from $63.00 to $23.00 and set an "outperform" rating on the stock in a research report on Thursday, January 16th. Six investment analysts have rated the stock with a hold rating and eight have given a buy rating to the company's stock. According to MarketBeat, Keros Therapeutics currently has an average rating of "Moderate Buy" and a consensus target price of $40.33.

Keros Therapeutics Trading Up 0.9 %

Keros Therapeutics stock traded up $0.13 during midday trading on Thursday, hitting $14.57. 689,118 shares of the stock were exchanged, compared to its average volume of 807,922. The stock has a market capitalization of $591.70 million, a price-to-earnings ratio of -2.80 and a beta of 1.39. The stock's 50-day simple moving average is $11.77 and its 200 day simple moving average is $26.96. Keros Therapeutics, Inc. has a fifty-two week low of $9.12 and a fifty-two week high of $72.37.

Keros Therapeutics (NASDAQ:KROS - Get Free Report) last posted its earnings results on Wednesday, February 26th. The company reported ($1.14) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.36) by $0.22. Keros Therapeutics had a negative return on equity of 41.74% and a negative net margin of 27,890.94%. The company had revenue of $3.04 million during the quarter, compared to analysts' expectations of $37.32 million. Equities analysts anticipate that Keros Therapeutics, Inc. will post -4.74 EPS for the current fiscal year.

Insider Buying and Selling

In other news, major shareholder Adar1 Capital Management, Llc bought 934,258 shares of Keros Therapeutics stock in a transaction that occurred on Wednesday, April 9th. The shares were purchased at an average price of $10.13 per share, with a total value of $9,464,033.54. Following the completion of the acquisition, the insider now directly owns 4,392,737 shares in the company, valued at $44,498,425.81. The trade was a 27.01 % increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. 22.90% of the stock is owned by corporate insiders.

About Keros Therapeutics

Keros Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis.